# A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

> **NCT04578535** · PHASE1 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 51 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** HYQVIA
- **DRUG:** HYQVIA
- **DRUG:** HYQVIA
- **DRUG:** HYQVIA
- **DRUG:** HYQVIA
- **DRUG:** HYQVIA

## Key facts

- **NCT ID:** NCT04578535
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-27
- **Primary completion:** 2022-03-02
- **Final completion:** 2022-03-02
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578535, "A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04578535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*